Cobalt administration causes reduced contractility with parallel increases in TRPC6 and TRPM7 transporter protein expression in adult rat hearts by Laovitthayanggoon, Sarunya et al.
Laovitthayanggoon, Sarunya and Henderson, Catherine J. and 
McCluskey, Claire and Macdonald, Margaret and Tate, Rothwelle J. and 
Grant, M. Helen and Currie, Susan (2018) Cobalt administration causes 
reduced contractility with parallel increases in TRPC6 and TRPM7 
transporter protein expression in adult rat hearts. Cardiovascular 
Toxicology. ISSN 1559-0259 , http://dx.doi.org/10.1007/s12012-018-9498-3
This version is available at https://strathprints.strath.ac.uk/66311/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Vol.:(0123456789) 
Cardiovascular Toxicology 
https://doi.org/10.1007/s12012-018-9498-3
Cobalt Administration Causes Reduced Contractility with Parallel 
Increases in TRPC6 and TRPM7 Transporter Protein Expression in Adult 
Rat Hearts
Sarunya Laovitthayanggoon1 · Catherine J. Henderson1 · Claire McCluskey2 · Margaret MacDonald2 · 
Rothwelle J. Tate2 · M. Helen Grant1 · Susan Currie2 
 
© The Author(s) 2018
Abstract
Exposure to circulating cobalt  (Co2+) in patients with metal-on-metal orthopaedic hip implants has been linked to cardiotox-
icity but the underlying mechanism(s) remain undeined. The aim of the current study was to examine the efects of  Co2+ on 
the heart in vivo and speciically on cardiac ibroblasts in vitro. Adult male rats were treated with  CoCl2 (1 mg/kg) for either 
7 days or 28 days. Inductively coupled plasma mass spectrometry (ICP-MS) was used to measure  Co2+ uptake into various 
organs of the body.  Co2+ accumulated in the heart over time with signiicant levels evident after only 7 days of treatment. 
There was no evidence of cardiac remodelling following  Co2+ treatment as assessed by heart weight:body weight and left 
ventricular weight:body weight. However, a decrease in fractional shortening, as measured using echocardiography, was 
observed after 28 days of  Co2+ treatment. This was accompanied by increased protein expression of the ion transient receptor 
potential (TRP) channels TRPC6 and TRPM7 as assessed by quantitative immunoblotting of whole cardiac homogenates. 
Uptake of  Co2+ speciically into rat cardiac ibroblasts was measured over 72 h and was shown to dramatically increase 
with increasing concentrations of applied  CoCl2. Expression levels of TRPC6 and TRPM7 proteins were both signiicantly 
elevated in these cells following  Co2+ treatment. In conclusion,  Co2+ rapidly accumulates to signiicant levels in the heart 
causing compromised contractility in the absence of any overt cardiac remodelling. TRPC6 and TRPM7 expression levels 
are signiicantly altered in the heart following  Co2+ treatment and this may contribute to the  Co2+-induced cardiotoxicity 
observed over time.
Keywords Cardiotoxicity · Cobalt · Cardiac ibroblast · Transient receptor potential (TRP) channels · Divalent metal 
transporter channel 1 (DMT1)
Introduction
Cardiotoxicity is the most frequently encountered adverse 
efect contributing to attrition of new candidate pharma-
ceuticals, but it has not often been associated with use of 
medical devices. Hip joint replacements are one of the most 
successful elective surgeries, but they are not without their 
limitations. The most notorious of these limitations in recent 
years are the adverse efects associated with metal-on-metal 
(MoM) hip articulations, made of CoCr alloy, which have 
led to several implants being removed from use following 
release of warning alerts by the medicines and healthcare 
products regulatory agency (MHRA) [1]. Wear of these 
medical devices causes formation and release of nanopar-
ticulate debris of CoCr, and metal ions in patients. Both Co 
and Cr ions are released into the bloodstream. Co ions, being 
more soluble than Cr ions, enter the patients’ circulation and 
may evoke systemic adverse efects including cardiomyopa-
thy, CNS toxicity and hypothyroidism in the patients over 
time. Use of metal-on-metal articulations in hip replacement 
was at its height in 2006, but has now declined to contribute 
< 1.1% of total hip replacements implanted. Although most 
of the defective MoM designs have been removed from the 
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market through the actions of MHRA, there are still over 
10,000 patients in the UK alone with these implants still 
in situ. If an artiicial hip joint fails, revision surgery is car-
ried out to replace it, but this can involve considerable mor-
bidity risk for the patient. Currently, litigation against the 
manufacturers is in progress in many countries, led by the 
USA, and it is important to determine what controls suscep-
tibility to adverse efects, and how to limit further damage 
to the health of these patients.
Cardiotoxicity was irst associated with  Co2+ in the 1960s 
when beer drinkers in Canada showed symptoms of cardio-
myopathy after  Co2+ had been used as an antifoaming agent 
during the brewing process [2]. In some of the beer drinkers, 
malnutrition may have contributed to susceptibility to the 
efects of  Co2+, but several cases of cardiomyopathy have 
also been reported in metal workers [3, 4] and in patients 
with MoM implants in situ [5, 6]. Studies using echocardi-
ography have described altered diastole, severely reduced 
left ventricular systolic function and cardiac hypertrophy [7]. 
It has also been shown that  Co2+ accumulates in the hearts 
and other organs of animals treated with  Co2+ and also with 
CrCo alloy nanoparticles [8, 9]. The underlying mechanisms 
for  Co2+ transport into the cells of the heart remain unclear.
There are a large number of proteins dedicated to trans-
porting calcium  (Ca2+) and magnesium  (Mg2+) ions into 
cells, and across cellular compartments. These vital ions 
are versatile second messengers controlling signalling path-
ways which mediate many physiological and pathological 
processes.  Co2+ is also a divalent cation, and as such may 
enter cells by mimicking  Ca2+ and by using similar transport 
routes. TRP proteins belong to the TRP superfamily of  Ca2+ 
permeable channels exhibiting diverse tissue distribution, 
subcellular localisation, and physiological function and may 
play a role in  Co2+ uptake. Mammalian TRP channels can be 
divided into various subfamilies that include TRP canonical 
(TRPC1-6), TRP vanilloid (TRPV1-6) and TRP melastatin 
(TRPM1-8). Most of the TRP channels are located in the 
plasma membrane and function as the driving force for  Ca2+ 
and  Mg2+ transport [10]. Interestingly, some studies have 
indicated that  Co2+ may alter expression of TRP channels 
and be transported by these channels. Particular empha-
sis has been on TRPC6 and TRPM7 [11, 12]. Pertinent to 
the current study is the fact that TRP channels are highly 
expressed in the heart and have been widely studied in cardi-
omyopathy. High expression of TRPC1, TRPC3 and TRPC6 
genes are seen in heart disease and contribute to remodelling 
of the heart [13]. These channels are expressed across both 
contractile and non-contractile cells of the heart and directly 
inluence physiological and pathological responses of both 
[14]. It therefore seems possible that TRP channels may 
also be directly involved in cardiotoxic responses, such as 
those induced by  Co2+. Another transporter involved in the 
transport of divalent cations is divalent metal ion transporter 
1 (DMT1). This protein is known to transport iron and a 
range of other cations via a proton-coupled mechanism and 
is expressed in heart [15]. Co ions are predicted to enter 
brain cells via this transporter [16] and DMT1 in neurones 
has been shown to exhibit altered functional characteristics 
following exposure to  Co2+ [17]. Although nothing is known 
of whether DMT1 may be involved in  Co2+ uptake into the 
heart, evidence for involvement across other systems does 
make this a possibility.
Our hypothesis is that  Co2+ treatment impairs cardiac 
function in vivo and this impairment is relected at a cellu-
lar level where alterations in transporter proteins are evident. 
Experiments were designed to ind out if  Co2+ is cardiotoxic 
to animals dosed at concentrations that mimic the blood con-
centrations measured in MoM patients. Efects of  Co2+ on 
primary adult rat cardiac ibroblasts (CFs) were also investi-
gated since these cells are responsible not only for maintain-
ing the structural integrity of the heart, but also for modu-
lating electrical coupling between neighbouring myocytes 
[18]. A key advantage of focusing on adult CFs instead of 
the contractile myocytes is that the CFs can be maintained in 
culture over several passages, enabling longer-term investi-
gation of  Co2+ efects. This is not possible with adult cardiac 
myocytes that lose their characteristic adult phenotype very 
quickly in culture. Speciically, we have studied the uptake 
characteristics of  Co2+ into the organs of the body as well 
as into primary isolated CFs. Candidate proteins (TRPC6, 
TRPM7 and DMT1) that may regulate the uptake of  Co2+ 
into the heart have been examined. Parallel alterations in 
expression of each of these proteins were observed across 
whole cardiac tissue homogenates and CFs following  Co2+ 
treatment. This could highlight a role for these proteins in 
mediating the efects of  Co2+ in the heart.
Methods
In Vivo Cobalt Treatment and Echocardiography
Male Sprague–Dawley rats [200–300 g (8–10 weeks old)] 
were given intra-peritoneal (i.p.) injections of distilled water 
(n = 3) or 1 mg/kg  CoCl2 (n = 6) in distilled water daily for 
7 days and 28 days. The animals were subjected to echo-
cardiography (short-axis view) as previously described 
[19] at both 7 days and 28 days and then euthanised on the 
same day as the inal injection. Procedures complied with 
the ARRIVE guidelines and conformed to the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health (NIH Publication No. 85-23, 
revised 1996) and Directive 2010/63/EU of the European 
Parliament. Blood was collected by cardiac puncture and 
speciic organs (liver, brain, spleen, heart, lungs, kidneys 
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and testes) were removed, weighed and then collected for 
further analysis by ICP-MS.
Body weights were recorded daily (in the morning). 
Recording body weight during  Co2+ treatment provides an 
indicator of the general health status of the rats that may be 
relevant in the interpretation of toxic efects.
ICP‑MS Analysis
Blood (0.5 mL), organ samples (100 mg) or cells (conluent 
35 mm2 dish) were digested with 0.5 mL of  HNO3 [70% 
(v/v)] and heated at 103 °C for 20 min. Hydrogen perox-
ide  [H2O2, 30% (w/v)] (0.25 mL) was added and the diges-
tion continued for a further 20 min. Samples were stored at 
− 20 °C prior to metal analysis. For analysis, samples were 
thawed and diluted 40-fold (cell lysates tenfold) in ultrapure 
water containing 1% (v/v)  HNO3.  Co
2+ standards (range 0, 
50, 100, 250, 500 and 1000 µg/L) were prepared by diluting 
1000 mg/L  CoCl2 (TraceCERT®) with  HNO3. Samples and 
standards were analysed using an Agilent 7700× octopole 
collision system ICP-MS (Agilent Technologies; Woking-
ham, UK) in helium gas mode using Scandium (Sc, 3 ppm) 
as an internal standard. The quantiication was based on the 
maximum signal for a particular isotope, also referred to 
as peak height. The limit of detection for  Co2+ is 0.3 ng/L 
and the limit of quantiication is 1 ng/L. Five readings were 
taken, and the result obtained is the mean value.
Cardiac Fibroblast Isolation, Culture and  Co2+ Treat‑
ment
CFs were isolated by bulk digestion using collagenase and 
protease as previously described [20]. Cells were cultured 
at 37 °C and 5%  CO2 in Dulbecco’s Modiied Essential 
Medium (DMEM) containing 20% foetal calf serum (FCS) 
and were passaged at ~ 80% conluence. CFs were only used 
up to passage 3 as we noted a myoibroblast phenotype start-
ing to emerge beyond this point. For treatment with  Co2+ 
and further analysis by immunoblotting, cells were seeded 
into T25 lasks at a density of 1 × 105 cells/mL. After 24 h, 
 CoCl2 (10 µM) was added and cells were left for either 48 h 
or 72 h prior to stopping the treatment. At the end-point, cul-
ture medium was discarded and cells were washed in PBS. 
Homogenisation bufer (300 µL) (0.1 M  Na2PO4, pH 7.6, 
500 µM 4-(2-aminoethyl) benzenesulfonyl luoride hydro-
chloride (AEBSF), 150 nM Aprotinin, 1 µM E−64 and 
1 µM leupeptin) was added, cells scraped from the lasks 
and homogenised using seven strokes of a motor-driven 
Telon-glass homogeniser. Homogenates were aliquoted and 
stored at − 80 °C with one aliquot reserved for total protein 
quantiication.
Measurement of Total Protein Content
Total protein was measured using a Lowry assay [21] with 
bovine serum albumin (BSA) used at a range of concentra-
tions (0–200 µg/mL) to generate a standard curve.
Immunoluorescence
CFs and colonic vascular smooth muscle cells (rat primary 
cells, used as a positive control) were grown on coverslips 
until conluent and ixed in 4% (v/v) paraformaldehyde. 
Cells were exposed to cold methanol then washed in PBS 
and permeabilised with Triton X-100 [0.01% (v/v)] for 
10 min. Non-speciic binding was blocked using 1% (w/v) 
bovine serum albumin (BSA) followed by application of pri-
mary antibody [vimentin (abcam #Vim3B4) and α-smooth 
muscle actin (Sigma-Aldrich #A5228)] overnight at 4 °C. 
Anti-mouse IgG-FITC (Sigma-Aldrich#FO257) (1:1000) 
was then applied and coverslips mounted on to slides using 
Mowiol® (Sigma-Aldrich) mounting medium containing 
4ƍ,6-diamidino-2-phenylindole (DAPI) (Vecta laboratory). 
The DAPI counter-stain in the mounting medium stained 
the cell nuclei blue.
MTT (3‑(4,5‑Dimethylthiazol‑2‑yl)‑2,5‑Diphe‑
nyltetrazolium Bromide) Assay
CFs were plated in a 96-well plate at  104 cells/cm2 and a 
range of  CoCl2 concentrations [0–25 µM (low concentration 
range) or 0–1000 µM (high concentration range)] added. 
Incubations were performed for 24, 48 and 72 h. MTT was 
added for 4 h and absorbance measured at 540 nm.
Quantitative Immunoblotting
Samples (homogenised cardiac tissue or CFs) were analysed 
by immunoblotting using the NuPAGE system as previ-
ously described [19, 20]. DMT1 protein was detected using 
an overnight incubation in anti-DMT1 (rabbit polyclonal, 
Sigma-Aldrich) at 1:800 dilution. TRPM7 and TRPC6 pro-
teins were detected using anti-TRPM7 (rabbit polyclonal, 
Abcam) at 1:500 dilution and TRPC6 (rabbit polyclonal, 
Sigma–Aldrich) at 1:500 dilution, respectively. GAPDH pro-
tein was detected as a loading control (mouse polyclonal, 
Abcam). All membranes were then subjected to a 2-h incu-
bation in peroxidase-conjugated anti-rabbit or anti-mouse 
IgG prior to incubation in chemiluminescence reagent and 
exposure onto X-ray ilm. Protein bands were quantiied 
using a GS-800 imaging densitometer and Quantity One 
software (BioRad).
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Statistical Analysis
Results are expressed as mean values ± S.E.M. of n obser-
vations, where n represents the number of samples. Com-
parisons were assessed using the student’s t-test or one-way 
ANOVA with Dunnett’s post-test as indicated. Diferences 
were considered statistically significant when p < 0.05. 
Where no p value is shown, p > 0.05.
Results
Efects of  Co2+ Treatment on Body Weight 
and Individual Organ Weight
Adult male rats were treated with 1  mg/kg  CoCl2 as 
described in “Methods” section. Body weight was meas-
ured on each day of treatment and recorded. Data show that 
body weight increased over the period of treatment and the 
% body weight gain (calculated as a percentage of the initial 
body weight on day 0) is shown over 7 days and 28 days 
(Fig. 1a, b). After 7 days of treatment, there was no dif-
ference between control and  Co2+-treated animals, how-
ever, from day 8 onwards there were signiicant diferences 
between the groups. In addition to checking body weights, 
the weights of individual organs were also recorded from 
each animal. This is an important consideration for toxicol-
ogy studies since signiicant diferences in organ weights 
between control and treatment groups might occur in the 
absence of any morphological changes. Organ weight data 
are shown as the ratio of organ weight:body weight to 
account for any diferences in body weight between animals 
(Fig. 1c, d). No signiicant diferences were apparent in any 
of the organs measured.
Cobalt Uptake into Individual Organs
The distribution of Co ions into the organs and blood of 
 Co2+-treated rats following either 7 days or 28 days of treat-
ment was investigated using ICP-MS and measured as ng/g 
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Fig. 1  The efect of  Co2+ treatment on body weight and organ weight. 
Adult male rats were given daily i.p. injections of 1 mg/kg  CoCl2 or 
distilled water (control) for either 7 days or 28 days. Triangles in a, b 
represent the body weight gain of rats in control groups (n = 3) and 
squares represent the body weight gain of rats in the Co treated group 
(n = 6). Data are presented as the % weight gain over time compared 
to day 0. c, d show histograms representing the organ weights from 
rats in the control group (n = 3) and Co-treated group (n = 6) at 7 days 
(c) and 28  days (d). Data are presented as the percentage of organ 
weight/body weight. All data are presented as mean ± SEM, (two-
sample t-test, *p < 0.05 with respect to control)
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(Fig. 2).  Co2+ was found to enter all the organs of rats over 
the period of treatment and there were signiicant diferences 
in organ content of  Co2+ between treated animals and those 
that had no metal ion treatment. Signiicant accumulation 
of  Co2+ in heart, kidney, brain and spleen occurred over 
7 days and levels continued to increase up until 28 days. 
The two organs that accumulated most  Co2+ were liver and 
kidney (~ 2000 ng/g) and the  Co2+ content was 4- to 40-fold 
higher than that seen in other organs. The  Co2+ concentra-
tion in whole blood taken from  Co2+-treated rats was almost 
100-fold more than blood from untreated rats. The hearts 
of  Co2+-treated rats had ~ sixfold greater levels of  Co2+ 
after 7 days of treatment and these levels almost doubled 
(~ 11-fold) following 28 days of treatment.
Efects of  Co2+ on In Vivo Cardiac Contractile Perfor‑
mance
Contractile performance of the hearts of  Co2+-treated (n = 6) 
and untreated (n = 3) animals from both the 7 days of group 
and the 28 days of group was monitored by echocardiogra-
phy and % fractional shortening (%FS) calculated. Typical 
motion-mode traces taken from the 28 days of group are 
shown in Fig. 3a (i). Left ventricular end-diastolic diam-
eter (LVEDD) and left ventricular end-systolic diameter 
(LVESD) were measured and used to calculate %FS. No 
diferences were apparent following 7 days of  Co2+ treat-
ment, however, after 28 days there was a small but signii-
cant reduction in %FS in the  Co2+-treated group (Fig. 3a 
(ii) and (iii)). Following echocardiography, whole heart 
wet weights as well as left ventricular wet weights were 
measured post-mortem and heart weight:body weight as 
well as LV weight:body weight ratios calculated. There was 
no diference in the ratios obtained between untreated and 
 Co2+-treated groups at either 7 days or 28 days, indicating no 
evidence for hypertrophic remodelling of the heart (Fig. 3b).
Co2+‑Induced Alterations in TRP Channels in Whole 
Heart
To identify possible mechanisms for  Co2+ uptake into the 
heart and to test whether chronic  Co2+ treatment might 
have the potential to alter these mechanisms, the expression 
of several ion transporter proteins was examined. Whole 
left ventricular cardiac homogenates (WH) were prepared 
from untreated rat hearts and from the hearts of rats treated 
with  CoCl2. WHs from rats that had been treated for either 
7 days or 28 days were assessed for expression levels of 
DMT1, TRPC6 and TRPM7 proteins using quantitative 
immunoblotting. Equivalent total protein loads (20 µg) 
were analysed and expression compared between control 
and treated samples for each individual protein (DMT1, 
TRPC6 and TRPM7). DMT1 was expressed at signiicantly 
higher levels in rat heart than either of the TRP channels. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
also detected and used as an internal control (Fig. 4a). To 
enable quantitative comparison, ratios were calculated for 
DMT1:GAPDH, TRPC6:GAPDH and TRPM7:GAPDH for 
WHs from untreated rats and  Co2+-treated rats at 7 days and 
28 days (Fig. 4b). Following 7 days of treatment there was a 
Group
Whole Blood
(µg/L)
Heart
(ng/g)
Liver
(ng/g)
Kidney
(ng/g)
Brain
(ng/g)
Lung
(ng/g)
Spleen
(ng/g)
Testes
(ng/g)
Control 1.14±0.09 47.62±15.74 92.98±24.37 257.61±30.77 15.48±2.63 23.52±8.14 28.58±6.67 15.38±5.06
CoCl2 1 
mg/kg BW 
(7 days)
99.01±13.83* 307.82±35.74* 1,839.86±177.30* 1,536.01±83.95* 46.85±3.97* 176.43±26.52* 185.59±13.92* 68.80±7.25*
CoCl2 1 
mg/kg BW 
(28 days)
121.00±9.88* 511.14±47.06*,# 1,928.02±90.64* 2,003.02±178.28*,# 87.76±10.58*,# 230.51±44.37* 324.44±63.67*,# 100.48±22.61*
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Fig. 2  Comparison of  Co2+ content across diferent organs follow-
ing  CoCl2 treatment. a Histogram showing  Co
2+ content in individ-
ual organs at day 0 (control), 7 days and 28 days following daily i.p. 
injections of 1 mg/kg  CoCl2. b Mean values from ICP-MS analysis 
in µg/L (whole blood) or ng/g (tissue) for  Co2+ found in each sample 
set. Control (n = 3) and  Co2+-treated groups (n = 6) were reported as 
mean values ± SEM, (one-way ANOVA,*p < 0.05 with respect to con-
trol and, #p < 0.05 comparing 7 and 28 days)
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signiicant drop in DMT1 protein expression in preparations 
from  Co2+-treated rats with no apparent changes in TRP 
channel expression. However, after 28 days of treatment, 
both TRPC6 and TRPM7 showed increased levels of expres-
sion with no changes in DMT1.
Efects of  Co2+ on the Viability of Cardiac Fibroblasts
In order to understand more about where in the heart TRPC6 
and TRPM7 channels may be of importance in mediating 
the efects of  Co2+, speciic examination of rat CFs was per-
formed. These non-contractile cells play an essential role 
in maintenance of cardiac extracellular matrix and struc-
ture as well as inluencing cardiac myocyte function. The 
substantial plasticity of these cells is still under investiga-
tion but evidence strongly suggests that CFs play a criti-
cal role in cardiac pathophysiology [22].  Co2+ uptake into 
adult rat CFs over 72 h was measured using ICP-MS. Ini-
tially, we identiied these cells based on vimentin staining 
and lack of smooth muscle actin staining (Fig. 5a). For 
uptake into the cells, a range of  CoCl2 concentrations was 
assessed (0–300 µM) and there was signiicant uptake into 
CFs at concentrations > 100 µM (Fig. 5b). The level of 
intracellular  Co2+ following treatment with 25 µM  CoCl2 
was 1.36 ± 0.15 µg/L rising to 8.09 ± 0.4 µg/L with 100 µM 
 CoCl2. Following treatment with 300 µM  CoCl2, intracel-
lular  Co2+ levels increased to 118.66 ± 7.7 µg/L. As  Co2+ 
uptake into cells increased with increasing concentrations 
of extracellular  CoCl2, there was a concentration-dependent 
efect on cell viability with concentrations > 100 µM result-
ing in reduced viability after 72 h as assessed by MTT assays 
(Fig. 5c). In order to quantify expression of potential  Co2+ 
transporter proteins in CFs following exposure to  CoCl2, 
we wanted to ensure that cell viability was not afected. 
Therefore, we chose to examine the efects of a lower con-
centration of  CoCl2 (10 µM) on protein expression. This 
concentration has no efect on CF viability as assessed by 
MTT assay following 72-h treatment (Fig. 5d).
Co2+‑Induced Alterations in TRP Channels in Cardiac 
Fibroblasts
CFs were treated with 10 µM  CoCl2 for up to 72 h and the 
efect on DMT1, TRPC6 and TRPM7 protein expression 
assessed by quantitative immunoblotting. All three proteins 
were expressed in CFs with DMT1 expressed at higher levels 
Group
LV end-
diastolic 
diameter
(LVEDD:cm)
LV end-
systolic 
diameter 
(LVESD:cm)
%Fractional 
shortening
Left Ventricular Posterior 
wall (LVPW;cm.)
Diastolic(d) Systolic (s)
Control (7 Days) 0.56 ± 0.04 0.20 ± 0.02 64.97 ± 0.91 0.19 ± 0.01 0.33 ± 0.01
CoCl2 1 mg/kg BW (7 Days) 0.49 ± 0.02 0.19 ± 0.01 61.19 ± 2.05 0.22 ± 0.01 0.33 ± 0.01
Control (28 Days) 0.57 ± 0.01 0.23 ± 0.00 60.29 ± 0.53 0.20 ± 0.01 0.32 ± 0.02
CoCl2 1 mg/kg BW (28 Days) 0.52 ± 0.02 0.24 ± 0.01 54.01 ± 0.90* 0.22 ± 0.01 0.31 ± 0.01
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Fig. 3  Chronic  Co2+ treatment reduces fractional shortening in the 
absence of cardiac remodelling in vivo. a (i) Echocardiogram show-
ing M-mode traces in the parasternal short-axis view of the left ven-
tricle (LV) performed in control rats (n = 3) and  Co2+ treated rats 
(n = 6) as indicated. ESD end-systolic diameter, EDD end-diastolic 
diameter, AW anterior wall, PW posterior wall. a (ii) Table comparing 
the echocardiographic parameters of ventricular performance between 
control and  Co2+-treated groups. a (iii) Histogram comparing frac-
tional shortening between control and  Co2+-treated groups at 7 days 
and 28 days. b Represents the heart weight and left ventricular weight 
of rats in the control group and  Co2+-treated group. Data are pre-
sented as the ratio of heart weight and left ventricular weight to body 
weight ± SEM, (two-sample t-test, *p < 0.05 with respect to control)
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that either TRPC6 or TRPM7. After 48-h treatment, DMT1 
levels were signiicantly decreased with signiicant increases 
in the levels of both TRP channels. At 72 h, there was no 
obvious effect of  Co2+ on DMT1 expression; however, 
both TRPC6 and TRPM7 proteins were again signiicantly 
increased in the presence of  CoCl2 (Fig. 6a, b).
Discussion
To our knowledge, this is the irst time that  Co2+-induced 
events in the whole heart have been linked with efects 
that are induced in the non-contractile cells of the heart. 
 Co2+ is rapidly taken up and distributed throughout all the 
main organs of the body with signiicant levels found in 
the heart after just 7 days of treatment (Fig. 2). Although 
there are no obvious signs of organ remodelling or hyper-
trophy over the 28 days of treatment period, the animals 
receiving  CoCl2 do show a signiicant reduction in weight 
gain after the irst week of treatment (Fig. 1). This efect 
has been reported previously in other species and it has 
been suggested that  Co2+ can induce as much as 20–30% 
weight loss over a period of 10 weeks in dogs, albeit at 
higher concentrations than used in the current study [23]. 
This could be due to actions of  Co2+ on the CNS to regu-
late appetite [24]. Cardiac function is altered after 28 days 
of treatment with  CoCl2 (1 mg/kg) whereby % fractional 
shortening is signiicantly reduced (Fig. 3a). The dose of 
 CoCl2 used in the current study is very low when com-
pared with the lethal dose  (LD50 = 35 mg/kg) previously 
calculated for rats [25] and this is pertinent when study-
ing the potential that  Co2+ has for cardiotoxic efects. The 
rationale for choosing 1 mg/kg as a dose was to demon-
strate that even at this low level (much lower than the 
lethal dose) there are detrimental efects on contractile 
function of the heart. This is in line with previous work 
where administration of 5 mg/kg i.p. twice a day caused a 
10% reduction in fractional shortening [26]. In examining 
the echocardiographic parameters of  Co2+-treated rats in 
the current study, the key diference between untreated and 
 Co2+-treated animals appears to be in the end-diastolic 
diameter measurement suggesting there may be impaired 
relaxation of the heart after 28 days of  Co2+ treatment. 
This could imply some stifening or ibrosis of the heart at 
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Fig. 4  Chronic  Co2+ treatment increases TRP channel expression in 
the heart. a Representative immunoblots of whole cardiac left ven-
tricular homogenates (20  µg) from control and 7-day or 28-day 
 Co2+-treated animals. Blots were probed for either DMT1, TRPC6 
and TRPM7 and protein expression quantiied using GAPDH as an 
internal control. b Histograms showing mean data presented as ratios 
of DMT1:GAPDH, TRPC6:GAPDH, or TRPM7:GAPDH from con-
trol (n = 3) and  Co2+-treated (n = 6) groups following 7  days and 
28 days of treatment. Data are presented as means ± S.E.M. and sta-
tistical analysis performed using two-sample t-tests (n ≥ 3, *p < 0.05, 
treatment group vs. control group)
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this stage as a result of efects of  Co2+ on CFs—the cells 
responsible for extracellular matrix production. That said, 
there are no obvious signs of cardiac remodelling even 
after 28 days (Fig. 3b).
It is important to note that treatment of rats with 1 mg/
kg  CoCl2 resulted in levels of  Co
2+ in whole blood ~ 100-
fold higher than untreated animals, 99.01 ± 13.83 and 
121 ± 9.88 µg/L on 7 days and 28 days, respectively (Fig. 2). 
This relates to patients with MoM implants where  Co2+ lev-
els in serum are more than 100-fold that of physiological 
levels (≤ 0.29 µg/L) [27]. One case study reported levels 
of  Co2+ in patients with MoM implants as 23 µg/L and this 
corresponded with diastolic dysfunction [28]. It is clear that 
there is signiicant patient to patient variability in terms of 
circulating  Co2+ from implants. Data from a recent system-
atic review suggest a mean blood  [Co2+] of 324 µg/L with 
some patients showing < 20 µg/L. What is apparent is that 
higher circulating  Co2+ results in more marked cardiotoxic-
ity [29]. Importantly, the circulating levels of  Co2+ in the 
rats used in this study are within the range of the levels 
found in patients with hip implants and since we used young 
(8–10 weeks), healthy adult rats in this study, there are no 
inherent cardiovascular problems associated with ageing that 
could impact on our results.
The efects of  Co2+ on contractile performance in the cur-
rent study could be a result of direct efects on the contractile 
cardiac myocytes and/or indirect efects on CFs. Either way, 
in order for  Co2+ to exert its efects on the heart there must 
be eicient cellular uptake mechanisms available to enable 
rapid entry of the ion to the target cells. We have examined 
the efects of  Co2+ treatment on three ion channels/transport-
ers (DMT1, TRPC6 and TRPM7) all of which are expressed 
in the heart and could potentially transport  Co2+. Initial data 
from left ventricular cardiac homogenates prepared from 
control and  Co2+-treated rats suggest that chronic (28 day) 
treatment leads to signiicant increases in TRP channel 
(TRPC6 and TRPM7) expression. These channels may be a 
route by which  Co2+ enters cardiac cells and may also be a 
means by which it exerts its cardiotoxic efects.
Based on our in vivo indings suggesting that  Co2+ causes 
impaired cardiac relaxation, we examined whether  Co2+ 
may speciically target and cause efects on CFs.  CoCl2 is 
eiciently taken up into CFs. Increasing the concentration 
of extracellular  Co2+ leads to a signiicantly greater intra-
cellular concentration (Fig. 5a). Importantly, as intracellu-
lar  Co2+ levels rise, CF viability decreases. This becomes 
particularly obvious at high extracellular  Co2+ concentra-
tions of > 100 µM (Fig. 5b). CF viability is not afected at 
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Fig. 5  Co2+ is transported into cardiac ibroblasts and reduces cell 
viability. a CFs stained with (i) vimentin and DAPI and (ii) α-smooth 
muscle action and DAPI. (iii) Rat vascular smooth muscle cells 
stained with α-smooth muscle actin and DAPI. b Histogram show-
ing ICP-MS analysis of intracellular  Co2+ levels in CFs exposed to 
increasing concentrations of  CoCl2 (0–300 µM) for 72 h. c Histogram 
showing % cell viability analysed by an MTT assay following expo-
sure of CFs to high concentrations (0–1000  µM) of  CoCl2 for 72  h 
and d a line graph showing % cell viability as assessed by MTT assay 
following exposure to a range of low concentrations (0–25  µM) of 
 CoCl2 for 72 h. Results are expressed as mean values ± SEM. Statis-
tical analysis was carried out using one-way-ANOVA with post hoc 
Dunnett’s comparison (n = 3, *p < 0.05)
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concentrations of 25 µM  Co2+ and below (Fig. 5c). In order 
to examine whether TRP channel expression is speciically 
altered in CFs, we treated cells with low levels (10 µM) of 
 CoCl2, a concentration we knew would not afect viability 
but may impact on cellular function and may be more in line 
with the concentration used for our in vivo work. Intrigu-
ingly, and in line with results from homogenised ventricular 
tissue, we found that TRP channel expression was signii-
cantly increased after both 48-h and 72-h treatments with 
10 µM  Co2+ (Fig. 6). The fact that  Co2+ application to CFs 
directly results in altered TRP channel expression may sug-
gest involvement of these channels in  Co2+-mediated cardiac 
efects. TRPC6 and/or TRPM7 could be a key route of entry 
for  Co2+ into CFs. By efecting an up-regulation of these 
channels,  Co2+ may be exerting a positive feedback loop 
enabling more eicient entry to the cells and expediting a 
cardiotoxic response.
Cardiotoxicity associated with  Co2+ has not previ-
ously been linked with CF function, yet these cells are 
of paramount importance in maintaining a healthy heart. 
CFs are quiescent under normal conditions but in response 
to pathological or toxic stimuli, can become hyper-pro-
liferative and secrete a variety of biochemical mediators 
that trigger the ibrotic response [30]. The efects that we 
observe on CF viability following treatment with high 
(> 100 µM)  CoCl2 concentrations in the current study do 
not indicate hyper-proliferation but instead show reduced 
viability and reduced potential for proliferation, probably 
as a result of cell damage at higher levels of intracellu-
lar  Co2+. Given these observations, it seems more likely 
that higher concentrations of  Co2+ would exert efects on 
viability rather than proliferation of CFs in the quiescent 
‘healthy’ heart. However, in patients with compromised 
cardiac function, such as pathological remodelling fol-
lowing a myocardial infarction or prolonged hyperten-
sion, where the proliferating CF is to the fore,  Co2+ could 
have a signiicant impact both on viability and proliferative 
potential. We did not assess collagen levels in this study 
but this is a feature of hyper-proliferation and ibrosis that 
could be assessed both in whole heart and at a cellular 
level following treatment with  CoCl2 to monitor produc-
tion of extracellular matrix. This would be important in 
determining any potential efects of  CoCl2 at a structural 
level and may link with our observations on altered TRP 
channel expression following 10 µM  CoCl2 treatment.
Ca2+ signalling plays a crucial role in mediating healthy 
CF function and TRP channels (TRPM7 in particular) have 
been shown to play a key role in regulating  Ca2+ entry to 
CFs in health and disease [31]. Of particular relevance to 
the current study, TRP channels, and TRPM7 speciically, 
have been shown to be up-regulated in patients with cardio-
vascular pathology. TRPM7 is up-regulated by 3- to ive-
fold in CFs from patients with atrial ibrillation compared 
with sinus rhythm patients [32]. It has been suggested that 
TRPM7-mediated  Ca2+ signalling could play a pivotal role 
in the development of ibrosis associated with cardiovascular 
disease and that TRPM7 could be an efective therapeutic 
target [14]. In addition to TRPM7, TRPC6 has also been 
associated with a disease-like phenotype for CFs. Evidence 
from a genome-wide screen has been presented to suggest a 
link between up-regulation of TRPC6 and healthy ibroblast 
to hybrid myoibroblast transformation [33]. Pro-ibrotic 
ligands such as TGFβ and angiotensin II cause up-regula-
tion and activation of TRPC6 and it has been suggested that 
inhibitors of TRPC6 could be efective in targeting ibrotic 
disease. It is pertinent that both TRP channels investigated 
in the current study and shown to be up-regulated by  Co2+ 
treatment, have direct links with a pathological phenotype 
when their levels and activity are up-regulated. Although 
we have not assessed TRP channel function in this study, it 
seems likely that the elevated protein expression following 
 Co2+ treatment is associated with increased activity.
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Fig. 6  Chronic  Co2+ treatment of cardiac ibroblasts causes increased 
expression of TRPC6 and TRPM7. a Cells were exposed to  CoCl2 
(10  µM) for 48 and 72  h and total cell extracts (50  µg loads/lane) 
analysed by immunoblot for DMT1, TRPC6 and TRPM7. GAPDH 
was detected and used as an internal control. b Histogram showing 
expression of each protein expressed as a ratio to the internal con-
trol (GAPDH) under control conditions and following treatment with 
 CoCl2. Data are presented as mean values ± SEM. Statistical analysis 
was carried out using a two-sample t-test (n ≥ 3, *p < 0.05, treatment 
group vs. control group)
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It is important to note that  Co2+ treatment has been used 
previously as a hypoxia mimetic in cell culture and acts 
to stabilise and up-regulate hypoxia inducible factor-1α 
(HIF1α) [34]. TRP channels can be activated by HIF1α and 
this may occur via direct binding of HIF1α to the TRP chan-
nel gene as has been shown for TRPA1 [35]. Whether this 
mechanism of action may be important for the efects of 
 Co2+ in CFs has not yet been examined but it could be a 
factor in the cardiotoxic response to  Co2+ exposure. As well 
as indirect efects on activation of TRP channels mediated 
via HIF1α,  Co2+ has also been suggested to directly block 
certain TRP channels.  Co2+ can compete with  Ca2+ and can 
bind to the ion selectivity ilter of TRPV1 so there appears to 
be a co-entry mechanism and competition for binding sites 
[36]. Whether  Co2+ competes with  Ca2+ entry in TRPC6 and 
TRPM7 in CFs remains to be established but these experi-
ments will be an important follow-up to the current study in 
elucidating the mechanism of action of  Co2+ in these cells 
and in the heart.
Up-regulation of both TRPC6 and TRPM7 as shown in 
the whole heart and the isolated CFs from  Co2+-treated ani-
mals could link with the compromised function we see in 
in vivo. It will be important to link changes in TRP channel 
function with altered expression and to establish whether 
inhibition of these  Co2+-induced efects may restore car-
diac contractile function. Investigation of the efects of 
TRPC6 and TRPM7 inhibition at the level of the CF will 
show whether there is a link between  Co2+-induced up-
regulation of these channels and abnormal cell function. 
As such, TRPC6 and TRPM7 targeted interventions could 
prove therapeutically useful in patients with MoM orthopae-
dic implants. Improved understanding of how  Co2+ enters 
the cells of the heart, as well as how it causes adverse cellu-
lar efects, should prove crucial in determining intervention 
strategies that could limit further damage to the cardiovas-
cular health of these patients.
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